Infectious Diseases (all articles)
New NICE Coronavirus Rapid Guidelines
3 May, 2020 | 22:46h | UTC- COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital – National Institute for Health and Care Excellence
- COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response – National Institute for Health and Care Excellence
- COVID-19 rapid guideline: children and young people who are immunocompromised – National Institute for Health and Care Excellence
See Previous NICE Coronavirus Guidelines: Rapid guidelines and evidence summaries – National Institute for Health and Care Excellence
Consensus Document: Restarting Planned Surgery in the Context of the COVID-19 Pandemic
3 May, 2020 | 22:43h | UTCRelated: New Scoring System to Prioritize Medically Necessary Operations (report and commentary)
Report: The Future of the COVID-19 Pandemic – Lessons Learned from Pandemic Influenza
3 May, 2020 | 22:36h | UTCNews Release: COVID-19: The CIDRAP Viewpoint
Public Health Measures and the Reproduction Number of SARS-CoV-2
3 May, 2020 | 22:23h | UTCPublic Health Measures and the Reproduction Number of SARS-CoV-2 – JAMA
Related Editorial: Public Health Interventions for COVID-19: Emerging Evidence and Implications for an Evolving Public Health Crisis – JAMA
Short Review: Coagulopathy Associated with COVID-19
3 May, 2020 | 22:09h | UTCCoagulopathy associated with COVID-19 – Canadian Medical Association Journal
Case Series: QT Intervals in Patients with COVID-19 Treated with Hydroxychloroquine Alone or in Combination with Azithromycin
3 May, 2020 | 22:01h | UTCCommentary: Beth Israel Deaconess Medical Center – Beth Israel Deaconess Medical Center
Related Studies: The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection – Circulation: Arrhythmia and Electrophysiology (link to abstract – $ for full-text) AND [Preprint] QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin – medRxiv
FDA Issues Emergency Use Authorization for the Use of Remdesivir to Treat COVID-19
3 May, 2020 | 22:03h | UTCSee also: Remdesivir: A Non-Antiviral Antiviral Drug? – Forbes
Drive-Through Testing for SARS-CoV-2
3 May, 2020 | 21:54h | UTC
Opinion: Pregnant Women Should be Given the Opportunity to be Included in Clinical Trials for COVID-19
3 May, 2020 | 21:51h | UTC“We recommend and urge the scientific community and professional societies that, without clear justification for exclusion, pregnant women should be given the opportunity to be included in clinical trials for COVID-19 based on the concepts of justice, equity, autonomy, and informed consent.”
SARS-CoV-2 Productively Infects Human Gut Enterocytes
3 May, 2020 | 21:52h | UTCSARS-CoV-2 productively infects human gut enterocytes – Science
Commentaries: SARS-CoV-2 Infection of Gut Organoids Bolsters Case for Intestinal Transmission – GEN AND Coronavirus SARS-CoV-2 infects cells of the intestine – Hubrecht Institute
Classification of the Cutaneous Manifestations of COVID‐19 with 375 Illustrative Cases
1 May, 2020 | 03:43h | UTCRelated: Journal articles on coronavirus with relevance for skin diseases and dermatology – Centre of Evidence Based Dermatology, University of Nottingham AND Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak – Journal of the American Academy of Dermatology
Great atlas with the different cutaneous manifestations of Covid-19.
CO-RADS – A Categorical CT Assessment Scheme for Patients with Suspected COVID-19
1 May, 2020 | 03:48h | UTC
Study Estimates the Impact of Social Distancing and School Closures on the Dynamics of the COVID-19 Outbreak
1 May, 2020 | 03:39h | UTCChanges in contact patterns shape the dynamics of the COVID-19 outbreak in China – Science
Related Commentary on Twitter
Just published: Major lessons from China on social distancing; school closing; children, young vs. adult impact for #COVID19https://t.co/wd3umeh46m
Social distancing: 7-8 X contact reduction
School closure: 40-60% reduction peak + delay
Continuum of age @ScienceMagazine pic.twitter.com/scrsvF3Pkq— Eric Topol (@EricTopol) April 29, 2020
Study: Within 19 Days After Symptom Onset, 100% of Patients Test Positive for IGG
1 May, 2020 | 03:33h | UTCAntibody responses to SARS-CoV-2 in patients with COVID-19 – Nature Medicine
Commentary: Expert reaction to antibody response in COVID-19 patients – Science Media Centre
Preprint Study Suggests Children May Be as Infectious as Adults
1 May, 2020 | 03:36h | UTC
Small Observational Study Suggests Prophylactic LMWH Can Prevent COVID‐19 Disseminated Intravascular Coagulopathy
1 May, 2020 | 03:26h | UTCCOVID‐19 Coagulopathy in Caucasian patients – British Journal of Haematology
Treatment Considerations for COVID-19: A Critical Review of the Evidence
1 May, 2020 | 03:20h | UTC
New Model to Track Covid-19 Spread
1 May, 2020 | 03:29h | UTCPopulation flow drives spatio-temporal distribution of COVID-19 in China – Nature
Commentary: Researchers devise new model to track COVID-19’s spread – Yale News
Perspective: Urging Caution on Remdesivir
1 May, 2020 | 03:07h | UTCUrging Caution On Remdesivir – Forbes
Related: About Remdesivir and About “Game-Changers” – Science Translational Medicine AND Conflicting Remdesivir Trial Results Released; Experts Urge More Research – Health Policy Watch AND Is remdesivir a miracle drug to cure coronavirus? Don’t get your hopes up yet – The Conversation AND PulmCrit- First placebo-controlled RCT on remdesivir for COVID-19 – PulmCrit AND Remdesivir: the antiviral drug is being touted as a possible coronavirus treatment – but will it work? – The Guardian
“While I have enormous respect for the Institutes and their leaders, releasing the preliminary news without sharing the data behind it is highly irresponsible.”
Clinical Determinants for Fatality of 44,672 Patients with COVID-19
1 May, 2020 | 02:48h | UTCClinical determinants for fatality of 44,672 patients with COVID-19 – Critical Care
Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
30 Apr, 2020 | 04:31h | UTCCommentaries: First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed – The Lancet AND Expert reaction to trial of remdesivir in adults – Science Media Centre
See also: [Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
Related Commentary on Twitter
With all the hype about Remdesivir today @TheLancet has decided to lift the embargo and release this placebo-controlled multicenter study done in China that showed no benefit https://t.co/ZdmKfnWLyw
— Carlos del Rio (@CarlosdelRio7) April 29, 2020
Pooling of Samples for Testing for SARS-CoV-2 in Asymptomatic People
30 Apr, 2020 | 04:25h | UTCPooling of samples for testing for SARS-CoV-2 in asymptomatic people – The Lancet Infectious Diseases AND Commentary: Virologists show that sample pooling can massively increase coronavirus testing capacity – Saarland University
Related Preprint Study: Smart Pooled sample Testing for COVID-19: A Possible Solution for Sparsity of Test Kits – medRxiv AND Commentary: ‘Smart sample pooling’ for COVID-19 could solve test kit shortage problem – News Medical
[Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
30 Apr, 2020 | 04:28h | UTCCommentaries: Hopes rise on coronavirus drug remdesivir – Nature AND The COVID-19 research news rollercoaster is running again: STAT News + Gilead’s remdesivir – HealthNews Review
See also: Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
Audio Interview: Loosening Covid-19 Restrictions
30 Apr, 2020 | 04:17h | UTCAudio Interview: Loosening Covid-19 Restrictions – New England Journal of Medicine
Men with COVID-19 Twice More Likely to Die than Women
30 Apr, 2020 | 04:21h | UTCNews Release: COVID-19 study shows that men have over double the death rate of women – Frontiers